OVARIAN CANCER and US: endometrioid ovarian cancer

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label endometrioid ovarian cancer. Show all posts
Showing posts with label endometrioid ovarian cancer. Show all posts

Monday, April 30, 2012

Endometriosis and ovarian cancer – Authors' reply : The Lancet Oncology



Endometriosis and ovarian cancer – Authors' reply : The Lancet Oncology


"Both Vercellini and colleagues and Guo and colleagues raise concerns about screening, with which we agree. Our findings should not suggest to clinicians or the public that screening for ovarian cancer should be implemented for women with endometriosis. Rather, we hope that our work stimulates further research that can refine risk groups related to endometriosis on the basis of anatomical site, epidemiological risk factors, or molecular features. Vercellini and colleagues raise an interesting point about atypical endometriosis, but this diagnosis is not standardised or commonly used and can not be addressed in epidemiological studies.
..................Regardless, the attenuated associations remain statistically significant.

(another) commentary: Endometriosis and ovarian cancer : The Lancet Oncology



Endometriosis and ovarian cancer : The Lancet Oncology

correspondence: Endometriosis and ovarian cancer : The Lancet Oncology



Endometriosis and ovarian cancer : The Lancet Oncology

Tuesday, March 13, 2012

abstract: Management and prognosis of endometrioid borderline tumors of the ovary



Management and prognosis of endometrioid borderline tumors of the ovary
Source: Surgical Oncology

Background 
The Endometrioid Borderline ovarian tumor (EBOT) is the third most common histological subtype of borderline ovarian tumors. Very little is known about the prognosis and management of this entity. This paper consists of a review of the literature and an analysis of clinical series.

Study design 
A review of the literature on this topic was conducted identifying series reporting consecutive cases of EBOT using 2 search engines (MEDLINE and Pubmed). Personal data on this topic have been included and concern a series of patients treated between 1985 and 2009 for EBOT. These cases included in this series had complete data concerning patient management and follow-up >12 months.

Results 
16 patients were studied: 7 had been treated conservatively and 9 radically. All 16/16 patients had stage I disease at the initial diagnosis but one patient had also developed synchronous endometrioid adenocarcinoma of the uterine corpus. After a median time of 24 months (range, 12–132) post treatment, one (1/16) patient had developed two recurrences. She remains disease-free 42 months after the end of treatment of the last recurrence. These data were compared to the results of 4 series previously reported in the literature. In fact, the present series reports on the first recurrence in EBOT (which was an invasive lesion).

Conclusion 
Endometrioid borderline ovarian tumors carry a good prognosis. Most EBOT tumors are stage I, therefore surgical staging is not necessary in most of the cases. However, uterine curettage is required in cases of uterine preservation.